siRNAgen Therapeutics

What siRNAgen Therapeutics does

siRNAgen Therapeutics is a privately-held clinical-stage biopharmaceutical company headquartered in Daejeon, Republic of Korea, founded in 2019 as a spin-out from BIONEER Corporation. The company develops RNAi therapeutics built on its proprietary SAMiRNA (Self-Assembled-Micelle Inhibitory RNA) delivery platform — a single-molecule self-assembling micelle architecture that protects siRNA from nuclease degradation and enables extrahepatic delivery to kidney, lung, skin, visceral fat, and brain via IV, intradermal, subcutaneous, and inhalation routes. This addresses the primary limitation of conventional siRNA therapeutics, which are largely restricted to hepatic targets. The platform is protected by 150+ approved and pending patents with completed Freedom to Operate, and the lead asset SRN-001 targets amphiregulin (AREG) for Idiopathic Pulmonary Fibrosis and is currently in Phase 1 clinical trials (Phase 1a complete in Australia September 2024; Phase 1b initiated under MFDS Korea approval in December 2025). A second candidate, SRN-002, targets osteoarthritis via intra-articular delivery in preclinical development, with additional programs in CKD, DKD, MASH, cancer, and radiation-induced pulmonary fibrosis.

The company operates a dual business model: proprietary drug development funded by parent BIONEER (a strategic platform established in 1992 supplying DNA/RNA synthesis products to 90+ countries), plus a CDMO services business launched in November 2024 that provides oligonucleotide manufacturing (up to 120 mmol per batch), RNAi high-throughput screening using automated ExiPrep/Exicycler systems, and in vivo CRO and histopathology services through a ~330 m2 Efficacy Evaluation Center in Daejeon. Revenue from CDMO services flows through custom quotations on inquiry, and licensing revenue derives from platform out-licensing including an exclusive May 2025 CNS deal with Cenos Therapeutics and an exclusive March 2023 technology license from BIONEER. Leadership includes Founder/CEO Dr. Han-Oh Park (BIONEER founder, 600+ global patents, recipient of Korea's Gold Tower Order of Industrial Service Merit, POSCO TJ Park Technology Award, and FACS Award), CTO Dr. Chun Geun Lee (Brown University professor), and VP of Operations Jae Mook Choi with 26+ years of R&D experience.

Customer segments are pharmaceutical and biotech companies requiring oligonucleotide CDMO partnerships, licensing partners for therapeutic co-development, and ultimately patients with fibrotic, oncologic, and immunologic diseases. Pricing is not publicly disclosed; the company reaches customers through direct email outreach, scientific publications (12 peer-reviewed papers), and conference participation. No external venture funding rounds are disclosed in the available data, and revenue figures are not publicly reported.

Name

siRNAgen Therapeutics

Legal name

siRNAgen Therapeutics

Website

https://sirnagen.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

siRNAgen Therapeutics is a Korea-based clinical-stage biotech developing extrahepatic RNAi therapeutics via its proprietary SAMiRNA delivery platform, with lead candidate SRN-001 in Phase 1 trials for IPF and a complementary CDMO services business serving pharma and biotech clients.

Ownership category

akta.pro rank

Product category

RNAi Therapeutics and Oligonucleotide CDMO

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

siRNA Therapeutics (gene silencing) (HLAAADAB)

akta.pro secondary industries

RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG), RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry) (HLAAADAE), mRNA/LNP & Nucleic Acid Therapeutics CDMO (HLAGABAF)

Keywords

• RNAi therapeutics
• SiRNA delivery
• Oligonucleotide manufacturing
• CDMO services
• Fibrosis drug development

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Supply Chain

Revenue model

1. CDMO Oligonucleotide Manufacturing Services: End-to-end CDMO services for oligonucleotide APIs from early development to commercial production. Services include oligo manufacturing (ASO, siRNA, aptamers, PMO, PPMO), process development, analytical validation, and GMP production with capacity up to 120 mmol per batch.
2. In Vivo CRO Services: Preclinical analytical services evaluating efficacy, toxicity, and pharmacokinetic properties of test substances in living organisms. Includes disease model establishment, dosing design, sample collection and analysis, and results reporting.
3. RNAi High-Throughput Screening Services: Comprehensive end-to-end RNAi drug development service covering candidate sequence design, synthesis, and in vitro and in vivo efficacy evaluation. Includes cytotoxicity testing and innate immunity assays.
4. Drug Pipeline Development: Development of proprietary RNAi therapeutics using SAMiRNA platform for fibrosis, cancer, immunology, and CNS disorders. Lead candidate SRN-001 in Phase 1 clinical trials for IPF.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

siRNAgen Therapeutics develops RNAi-based therapeutics built on its proprietary SAMiRNA nanoparticle delivery platform, which enables siRNA delivery beyond the liver to tissues such as lung, kidney, skin, visceral fat, and brain. The company also sells CDMO services covering oligonucleotide API manufacturing, RNAi high-throughput screening, and in vivo CRO with histopathology for external pharmaceutical and biotech clients. Revenue is generated from custom service engagements and from future licensing of the SAMiRNA platform.

Product overview

siRNAgen Therapeutics operates as both a biopharmaceutical company developing RNAi therapeutics and a CDMO (Contract Development and Manufacturing Organization) service provider. The company's core offering is the SAMiRNA® Platform—a proprietary self-assembled-micelle siRNA nanoparticle delivery technology that enables extrahepatic delivery of RNAi therapeutics. The therapeutic pipeline includes SRN-001 (Phase 1 for IPF using SAMiRNA-IV delivery) and SRN002 (preclinical for osteoarthritis using SAMiRNA-IA delivery), targeting fibrosis, cancer, immunology, and CNS disorders. The CDMO services segment provides oligonucleotide manufacturing (up to 120 mmol capacity), RNAi high-throughput screening with automated RT-qPCR systems, and in vivo CRO & histopathology services using validated disease models.

Differentiator

Problem solved

Functional benefit

Brands

• SAMiRNA: Self-Assembled-Micelle Inhibitory RNA - proprietary delivery platform for siRNA therapeutics that enables selective delivery to cancer and inflammatory tissues beyond the liver

Products and services

• SAMiRNA Platform Proprietary self-assembled-micelle siRNA nanoparticle delivery technology that forms spherical neutral nanoparticles from a DNA/RNA heteroduplex siRNA core with conjugated hydrophilic Hexaethylene glycol and hydrophobic hydrocarbon tails, enabling extrahepatic delivery to inflamed, adipogenic, and neoplastic tissues.
• SRN-001 (IPF therapeutic candidate) SAMiRNA-based siRNA drug candidate targeting amphiregulin (AREG) for the treatment of Idiopathic Pulmonary Fibrosis, currently in Phase 1a/1b clinical trials in Australia and Korea.
• SRN-002 (Osteoarthritis therapeutic candidate) SAMiRNA-based drug candidate for Osteoarthritis using intra-articular (SAMiRNA-IA) delivery, targeting underlying inflammation and cartilage protection in preclinical development.
• Oligonucleotide CDMO Manufacturing Service End-to-end contract manufacturing of oligonucleotide APIs from early development to commercial production, covering ASO, siRNA, aptamers, oligo conjugates, PMO, and PPMO modalities with GMP production up to 120 mmol per batch.
• RNAi High-Throughput Screening Service Comprehensive RNAi drug development service covering candidate sequence design, synthesis, and in vitro and in vivo efficacy evaluation using automated ExiPrep 96 Lite and Exicycler 384 systems with MIQE-compliant RT-qPCR testing, cytotoxicity assays, innate immunity assays, and IC50 determination.
• In Vivo CRO and Histopathology Service Preclinical in vivo experimental services evaluating efficacy, toxicity, and pharmacokinetics in disease animal models, including histopathological analysis (H&E and IHC staining), confocal microscopy, and efficacy evaluation at the 330 m2 Daejeon facility with capacity for 1,500 rodents.

Quantifiable outcome

• Validated in bleomycin-induced pulmonary fibrosis mouse models showing significant fibrosis reduction with AREG targeting SAMiRNA
• +4 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature7 records

Partnerships

Four partnerships are on record, tiered core and supporting.

• Cenos TherapeuticscoreStrategic or Co-development Partner · 1 May 2025Exclusive License Agreement executed May 2025 between siRNAgen and Cenos Therapeutics for SAMiRNA Glut CNS therapeutics. This partnership enables expansion of SAMiRNA platform applications into CNS disorders, leveraging Cenos Therapeutics' expertise in glutamatergic signaling and CNS drug development.
• Bioneer CorporationcoreOEM/ Whitelabel/ Licensing Partner · 1 March 2023Exclusive License Agreement executed March 2023 between Bioneer and siRNAgen for SAMiRNA technology. Bioneer is the parent company from which siRNAgen was spun off in 2019. Bioneer is Korea's first biotechnology company (established 1992) with global operations supplying DNA/RNA synthesis products and solutions to over 90 countries. Dr. Han-Oh Park is founder of both Bioneer and siRNAgen.
• Brown UniversitysupportingStrategic or Co-development PartnerCollaboration with Dr. Chun Geun Lee's research team at Brown University's Alpert Medical School (Department of Molecular Microbiology and Immunology) on SAMiRNA-based research for lung disease therapies. Dr. Lee serves as key member of siRNAgen's Scientific Advisory Board and leads research on molecular mechanisms of lung diseases including pulmonary fibrosis, emphysema, and asthma.
• Yale UniversitysupportingStrategic or Co-development PartnerDr. Chun Geun Lee completed postdoctoral training in Pulmonary and Critical Care Medicine at Yale University School of Medicine before joining Brown University. Academic collaboration contributes to scientific advisory expertise for siRNAgen's therapeutic development programs.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Market position

Competitive moat5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/sirnagen-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about siRNAgen Therapeutics